Company news

Cytokinetics, Incorporated news in 2026

Cytokinetics, Incorporated's news releases, calls and decks from 2026, newest first.

View company

Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update

November 4, 2026

Cytokinetics to Participate in November Investor Conferences

November 3, 2026

Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

November 2, 2026

Cytokinetics to Announce Third Quarter Results on November 4, 2026

October 21, 2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 19, 2026

Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

October 19, 2026

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026

October 12, 2026

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026

October 2, 2026

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

September 30, 2026

Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program

September 14, 2026

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

August 29, 2026

Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

August 20, 2026

Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026

Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

July 30, 2026

Cytokinetics to Announce Second Quarter Results on August 6, 2026

July 23, 2026

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

July 7, 2026

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

June 8, 2026

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

June 1, 2026

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

May 11, 2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million

May 8, 2026

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

May 6, 2026

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026

Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

May 5, 2026

Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026

May 4, 2026

Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress

April 28, 2026

Cytokinetics to Announce First Quarter Results on May 5, 2026

April 21, 2026

Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference

April 6, 2026

Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo

March 15, 2026

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

February 23, 2026

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

February 17, 2026

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

February 12, 2026

Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program

February 9, 2026

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

January 27, 2026

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

January 26, 2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 19, 2026

CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten)

January 12, 2026

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Calls in 2026

Decks in 2026